Evidence map›Paper›PMID 33438038›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2021

Simulated effects of early menopausal bone mineral density preservation on long-term fracture risk: a feasibility study.

E O Billington, W D Leslie, J P Brown, J C Prior, S N Morin, C S Kovacs, S M Kaiser, B C Lentle, T Anastassiades, T Towheed and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Consequences of Aging on Bone.Aging and disease · 2023
    Pooled it
  2. Women's perspectives regarding osteoporosis, fracture risk, and pharmacologic treatment: a cross-sectional study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023
    Article
  3. Article
  4. Article
  5. Mineral-rich water consumption as a non-pharmacological intervention for early menopausal bone mineral density preservation and reduction of long-term fracture risk: comment on Billington et al. Osteoporos Int. 2021;32(7):1313-20.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

E O BillingtonCumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. emma.billington@albertahealthservices.ca.ORCID http://orcid.org/0000-0002-2556-588X
W D LeslieDepartment of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
J P BrownDepartment of Medicine, Université Laval, Québec, Québec, Canada.
J C PriorFaculty of Medicine, Endocrinology/Medicine and Centre for Menstrual Cycle and Ovulation Research, University of British Columbia, Vancouver, British Columbia, Canada.
S N MorinDepartment of Medicine, McGill University, Montreal, Québec, Canada.
C S KovacsFaculty of Medicine - Endocrinology, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
S M KaiserDepartment of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
B C LentleDepartment of Radiology, University of British Columbia, Vancouver, British Columbia, Canada.
T AnastassiadesDepartment of Medicine, Queen's University, Kingston, Ontario, Canada.
T TowheedDepartment of Medicine, Queen's University, Kingston, Ontario, Canada.
G A KlineCumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Queen's University · CAUniversity of British Columbia · CAUniversity of Calgary · CADalhousie University · CAMcGill University · CAMemorial University of Newfoundland · CAUniversité Laval · CAUniversity of Manitoba · CA

Funding

Cumming School of Medicine, University of Calgary 10029917
6 · The paper itself

Abstract

Prevention of early menopausal bone loss may reduce the future burden of osteoporosis. In this modelling exercise, an osteoporosis prevention strategy involving 5-year infusions of zoledronic acid, beginning early in menopause, reduced long-term fracture risk and the proportion of aging women with femoral neck densitometric osteoporosis. This strategy warrants further evaluation.

introductionPreventing early menopausal bone loss may substantially reduce the future burden of osteoporosis. We modelled the effects of infrequent zoledronic acid infusions on long-term fracture risk.

methodsData from the Canadian Multicentre Osteoporosis Study (CaMos) were used to determine the expected natural history of femoral neck areal bone mineral density (BMD) and fracture risk (using FRAX®) from ages 50-80 for women with no antiresorptive drug exposures. We modelled the effects of three infusions of zoledronic acid (at ages 50, 55, 60) on long-term fracture risk, assuming this intervention would preserve BMD until age 65 years, followed by losses mirroring early menopausal BMD loss.

resultsAt age 65, untreated women and zoledronic acid recipients had expected mean (SD) femoral neck T-scores of - 1.5(1.0) and - 0.8(1.0), 10-year major osteoporotic fracture (MOF) risks of 9.8%(5.0) and 8.0%(3.7) and hip fracture risks of 1.7%(2.4) and 0.8%(1.2), respectively. At age 80, untreated women and zoledronic acid recipients had expected femoral neck T-scores of - 1.9(0.9) and - 1.4(0.9), MOF risks of 17.9%(8.2) and 14.9%(6.4) and hip fracture risks of 6.3%(6.2) and 4.4%(4.5), respectively. The expected proportion of women with femoral neck T-score ≤ - 2.5 was 14.9% for untreated women and 3.8% for zoledronic acid recipients at age 65, increasing to 28.1% and 12.0%, respectively, at age 80. Numbers-needed-to-treat to prevent one case of densitometric osteoporosis were 9 at age 65 and 5 at age 80.

conclusionInfrequent infusions of zoledronic acid, initiated early in menopause, are expected to reduce long-term fracture risk and result in a substantial reduction in the proportion of women with densitometric osteoporosis after age 65.

Indexed as

Bone DensityOsteoporotic FracturesAgedAged, 80 and overCanadaFeasibility StudiesFemaleHumansMenopauseMiddle AgedRisk AssessmentBisphosphonateBone mineral densityFracture riskFRAXOsteoporosisPrevention

Identifiers

PMID33438038
OpenAlexW3120307190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.